# PROpel (NCT03732820)

> Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03732820
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: olaparib; abiraterone acetate
- Enrollment: 895
- Primary outcome: Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment

## Indexed commentary on PROpel so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=propel-nct03732820